Aradigm Corporation  

(Public, NASDAQ:ARDM)   Watch this stock  
Find more results for OTC:ARDM
0.00 (0.00%)
Real-time:   3:02PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 6.17 - 15.00
Open     -
Vol / Avg. 0.00/4,385.00
Mkt cap 96.56M
P/E     -
Div/yield     -
EPS -0.29
Shares 14.75M
Beta 0.78
Inst. own 38%
Aug 10, 2015
Q2 2015 Aradigm Corp Earnings Release (Estimated) Add to calendar
May 11, 2015
Q1 2015 Aradigm Corp Earnings Release
Mar 17, 2015
Q4 2014 Aradigm Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -13.26% 13.86%
Operating margin -12.99% 14.92%
EBITD margin - -10.51%
Return on average assets -8.63% 8.91%
Return on average equity -12.08% 12.78%
Employees 18 -
CDP Score - -


3929 Point Eden Way
HAYWARD, CA 94545-3720
United States - Map
+1-510-2659000 (Phone)
+1-510-2658878 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Aradigm Corporation is a pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the treatment and prevention of severe respiratory diseases. The Company invested its capital to develop drug delivery technologies, particularly the development of pulmonary (respiratory) drug delivery as incorporated in its lead product candidate entering Phase III clinical trials, Pulmaquin. The Company has also invested in the generation of a large volume of laboratory and clinical data demonstrating the performance of its AERx pulmonary drug delivery platform and other proprietary technologies, including its inhaled ciprofloxacin formulations. The key technologies the Company has focused its efforts on are inhaled ciprofloxacin formulations and nicotine inhaler for smoking cessation.

Officers and directors

Virgil D. Thompson J.D. Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Igor Gonda Ph.D. President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Nancy E. Pecota Chief Financial Officer, Vice President - Finance
Age: 54
Bio & Compensation  - Reuters
Robert A. Reed Ph.D. Vice President - Regulatory (CMC) and Quality
Bio & Compensation  - Reuters
Juergen Froehlich M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
David Bell Director
Age: 60
Bio & Compensation  - Reuters
Frederick M. Hudson CPA Independent Director
Age: 69
Bio & Compensation  - Reuters
Lafmin Morgan Independent Director
Age: 50
Bio & Compensation  - Reuters
John M. Siebert Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters